Truist notes that AnaptysBio (ANAB) reported the “much anticipated” results of its Phase 2b trial of rosnilimab for moderate-to-severe rheumatoid arthritis and that the primary endpoint of DAS-28 CRP and key secondary endpoints were met. However, efficacy was numerically undifferentiated from peresolimab and the firm says rosnilimab “looks like a me-too in RA.” Confusion and questions around handing of the placebo group post double-blinded study period through week 12 raises questions about the veracity of week 14 data, adds the analyst, who keeps a Hold rating and $20 price target on AnaptysBio shares.

Maximize Your Portfolio with Data Driven Insights:

• Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.

• Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on ANAB:

• AnaptysBio Announces Promising Phase 2b RENOIR Trial Results

• AnaptysBio announces Phase 2b RENOIR trial met primary endpoint

• AnaptysBio’s Strong Financial Prospects Driven by Jemperli’s Growth and Strategic Partnerships

• Hold Rating for AnaptysBio: Strategic Licensing Decision Amid Limited GPP Market and Competitive Challenges

• AnaptysBio initiated with an Outperform at Wolfe Research